{"prompt": "['2017N323364_0', 'CONFIDENTIAL', '2019N398531_00', '207626', '12.4.', 'Appendix 4: Liver Safety: Required Actions and Follow-up', 'Assessments', 'Phase III-IV liver chemistry stopping and increased monitoring criteria have been', 'designed to assure participant safety and evaluate liver event aetiology (in alignment with', 'the FDA premarketing clinical liver safety guidance).', 'tp://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guid', 'ances/UCM174090.pdf', 'Phase III-IV liver chemistry stopping criteria and required follow up assessments', 'Liver Chemistry Stopping Criteria - Liver Stopping Event', 'Alanine', 'ALT 8x ULN', 'Transaminase', '(ALT)-', 'absolute', 'ALT Increase', 'ALT 5x ULN but <8x ULN persists for >2 weeks', 'ALT 3x ULN but <5x ULN persists for >4 weeks', 'Bilirubin1, 2', 'ALT 3x ULN and bilirubin 2x ULN (>35% direct bilirubin)', 'INR\u00b2', 'ALT 3x ULN and INR>1.5, if INR measured', 'Cannot', 'ALT 5x ULN but <8x ULN and cannot be monitored weekly for >2 weeks', 'Monitor', 'ALT 3x ULN but <5x ULN and cannot be monitored weekly for >4 weeks', 'Symptomatic\u00b3', 'ALT 3x ULN associated with symptoms (new or worsening) believed to be', 'related to liver injury or hypersensitivity', 'Required Actions and Follow up Assessments following ANY Liver Stopping Event', 'Actions', 'Follow Up Assessments', 'Immediately discontinue study treatment', 'Viral hepatitis serology4', 'Report the event to GSK within 24 hours', 'Only in those with underlying chronic', 'Complete the liver event eCRF and complete', 'hepatitis B at study entry (identified by', 'an SAE data collection tool if the event also', 'positive hepatitis B surface antigen)', 'meets the criteria for an SAE\u00b2', 'quantitative hepatitis B DNA and hepatitis', 'delta antibody5.', 'Perform liver event follow up assessments', 'Blood sample for pharmacokinetic', 'Monitor the participant until liver chemistries', 'analysis, obtained within 72 hours after', 'resolve , stabilize, or return to within baseline', 'last dose6', '(see MONITORING below)', 'Serum creatine phosphokinase and lactate', 'Do not restart/rechallenge participant with', '88']['2017N323364_0', 'CONFIDENTIAL', '2019N398531_00', '207626', 'study treatment unless allowed per protocol', 'dehydrogenase.', 'If restart/rechallenge not allowed per', 'Fractionate bilirubin, if total', 'protocol permanently discontinue study', 'bilirubin>2x ULN', 'treatment and may continue participant in the', 'study for any protocol specified follow up', 'Obtain complete blood count with', 'assessments', 'differential to assess eosinophilia', 'Record the appearance or worsening of', 'clinical symptoms of liver injury, or', 'hypersensitivity, on the AE report form', 'Record use of concomitant medications on', 'MONITORING:', 'the concomitant medications report form', 'including acetaminophen, herbal', 'For bilirubin or INR criteria:', 'remedies, other over the counter', 'Repeat liver chemistries (include ALT, AST,', 'medications.', 'alkaline phosphatase, bilirubin) and perform', 'Record alcohol use on the liver event', 'liver event follow up assessments within 24', 'alcohol intake case report form', 'hrs', 'Monitor participants twice weekly until liver', 'chemistries resolve, stabilize or return to', 'For bilirubin or INR criteria:', 'within baseline', 'Anti-nuclear antibody, anti-smooth muscle', 'A specialist or hepatology consultation is', 'antibody, Type 1 anti-liver kidney', 'recommended', 'microsomal antibodies, and quantitative', 'total immunoglobulin G (lgG or gamma', 'For All other criteria:', 'globulins).', 'Repeat liver chemistries (include ALT, AST,', 'Serum acetaminophen adduct HPLC', 'alkaline phosphatase, bilirubin) and perform', 'assay (quantifies potential acetaminophen', 'liver event follow up assessments within 24-', 'contribution to liver injury in participants', '72 hrs', 'with definite or likely acetaminophen use', 'in the preceding week [James, 2009]).', 'Monitor participants weekly until liver', 'NOTE: not required in China', 'chemistries resolve, stabilize or return to', 'within baseline', 'Liver imaging (ultrasound, magnetic', 'resonance, or computerised tomography)', 'and /or liver biopsy to evaluate liver', 'disease; complete Liver Imaging and/or', 'Liver Biopsy eCRF forms.', '1. Serum bilirubin fractionation should be performed if testing is available. If serum bilirubin fractionation is not', 'immediately available, discontinue study treatment for that partcipant if ALT 3x ULN and bilirubin 2x ULN.', 'Additionally, if serum bilirubin fractionation testing is unavailable, record presence of detectable urinary', 'bilirubin on dipstick, indicating direct bilirubin elevations and suggesting liver injury', '2.', 'All events of ALT 3x ULN and bilirubin 2x ULN (>35% direct bilirubin) or ALT 3x ULN and INR>1.5, if INR', \"measured which may indicate severe liver injury (possible 'Hy's Law'), must be reported as an SAE (excluding\", 'studies of hepatic impairment or cirrhosis); INR measurement is not required and the threshold value stated', 'will not apply to participants receiving anticoagulants', '3.', 'New or worsening symptoms believed to be related to liver injury (such as fatigue, nausea, vomiting, right upper', 'quadrant pain or tenderness, or jaundice) or believed to be related to hypersensitivity (such as fever, rash or', 'eosinophilia)', '89']\n\n###\n\n", "completion": "END"}